Showing results (151-160 of 831) with videos related to
Sort By:
Pageof 84
Leukemia Research|October 19, 2010
Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevanceWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.Leukemia Research|October 12, 2004
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assayIman Jilani, Michael Keating, Francis J Giles, et al.Cancer|July 29, 2009
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemiaNitin Jain, William Wierda, Alessandra Ferrajoli, et al.Seminars in Hematology|December 23, 2008
Epigenetics of acute lymphocytic leukemiaGuillermo Garcia-Manero, Hui Yang, Shao-Qing Kuang, et al.Cancer|September 5, 2002
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemiaRaymond Lai, Susan O'Brien, Taghi Maushouri, et al.Clinical Lymphoma, Myeloma & Leukemia|January 13, 2026
Real-World Evidence on Ibrutinib in First-Line Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma: A Comprehensive ReviewNilanjan Ghosh, John N Allan, Sabyasachi Ghosh, et al.Leukemia Research|July 26, 2005
A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cellsNeil E Kay, Nancy D Bone, Yean K Lee, et al.Leukemia Research|January 9, 2008
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?Tait D Shanafelt, Neil E Kay, Tim G Call, et al.The New England Journal of Medicine|August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D Shanafelt, Xin V Wang, Neil E Kay, et al.Leukemia & Lymphoma|July 2, 2013
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemiaPaolo Strati, Alessandra Ferrajoli, Susan Lerner, et al.Pageof 84